Survey Shows High Awareness and Potential for Rapid Adoption
QUEBEC CITY, June 14, 2012 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced that LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, has published an independent survey of 273 practicing urologists who answered within two days on their expected use of the PCA3 assay in men suspected of having prostate cancer.
"Based on the results of our proprietary survey we believe there is strong interest in the use of the test by both academic and community based urologists" said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "Almost half (49.6%) of the survey responders intend to test their patients with this assay, 47.4% report that they may use it, and only 4.1% do not expect to use the test."
DiagnoCure Inc. owns the exclusive worldwide diagnostic rights to the PCA3 marker which predicts the results of repeat biopsies more accurately than traditional PSA serum tests, known to have very high false positive rates. PCA3 identify patient at risk of prostate cancer following a first prostate biopsy and may help reduce unnecessary repeat prostate biopsies. DiagnoCure receives royalties on worldwide sales of the test.
Dr. McDonald's full Survey Report is available to download at no cost on the LifeSci Advisors website at http://lifesciadvisors.com/marketresearch/ and can also be accessed from DiagnoCure's website at www.diagnocure.com, through the hyperlink under the "Analysts" page of the "Investors" tab.
About LifeSci Advisors
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.
DiagnoCure (TSX: CUR) is a life sciences company that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Company launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and granted the worldwide exclusive rights to this test to Signal Genetics in June 2011. The Company has also granted a worldwide exclusive license agreement to Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and is now approved for commercialization in Canada and the United States. For more information, visit www.diagnocure.com.
This release contains forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward‐looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.
SOURCE DIAGNOCURE INC.